Bacteriostatic Antibiotics Market
Regional Analysis
North America Bacteriostatic
Antibiotics Market is expected to hold a dominant position in the global
Bacteriostatic Antibiotics Market and account for largest market share over the
forecast period, owing to presence of key players and approval and launch of
novel bacteriostatic antibiotics drugs by them in the region.
For instance, in August 2018,
Tetraphase Pharmaceuticals, Inc., a Massachusetts, U.S-based biopharmaceutical
company, received the U.S. Food and Drug Administration (FDA) approval for its
novel bacteriostatic antibiotics namely XERAVA (eravacycline) for the treatment
of complicated intra-abdominal infections (cIAI)
Antibiotics are naturally
occurring or artificially produced substances, which are widely used in the
treatment of bacterial diseases. Antibiotics works by killing bacteria
(bactericidal effect) or by inhibiting their growth (bacteriostatic effect).
Although bacteriostatic antibiotics prevent bacterial growth and reproduction,
it does not necessarily kill them.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/2307
Bacteriostatic Antibiotics Market
Drivers
Global bacteriostatic antibiotics
market is expected to witness a significant growth over the forecast period,
owing to recent approval and launch of novel bacteriostatic antibiotics
products in the market.
For instance, in September 2018,
Tetraphase Pharmaceuticals, Inc., a biopharmaceutical company dedicated to
development, manufacturing, and commercialization of novel antibiotics for
treat life-threatening multidrug-resistant (MDR) infections received European
Commission (EC) marketing authorization for its novel bacteriostatic antibiotic
namely XERAVA (eravacycline) injection, which is indicated for the treatment of
complicated intra-abdominal infections (cIAI) in adults in the European Union.
XERAVA (Eravacycline) is a fluorocycline antibacterial within the tetracycline
class of antibacterial drugs, it is bacteriostatic against gram-positive
bacteria (e.g., Staphylococcus aureus and Enterococcus faecalis)
Furthermore, high prevalence of
bacterial and infectious disease is expected to propel demand for
bacteriostatic antibiotics, in turn driving global bacteriostatic antibiotics
market growth.
For instance, according to the
data published by Centers of Disease Control and Prevention (CDC), in 2016, an
estimated 9,272 people suffered from tuberculosis, 53,850 from salmonella, and
36,429 from Lyme disease in the U.S.
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/bacteriostatic-antibiotics-market-2307
Bacteriostatic Antibiotics Market
Restraint
Some side effect associated with
bacteriostatic antibiotics may lower adoption of these drugs and hinder global
bacteriostatic antibiotics market growth. For instance, chloramphenicol, a type
of bacteriostatic antibiotic have severe side effects such as bone marrow
suppression, severe allergic reactions, and can also lead to mental disorders.
Furthermore, presence of
bactericidal antibiotics, which is an alternative of bacteriostatic antibiotics
may create an internal threat of substitute and hinder global bacteriostatic
antibiotics market growth.
Bacteriostatic Antibiotics Market
Key Players
Key players operating in global
Bacteriostatic Antibiotics Market include Tetraphase Pharmaceuticals, Inc.,
Allergan Plc., Pfizer Inc., Mylan N.V., Sun Pharmaceutical Industries Ltd.,
Hikma Pharmaceuticals Plc., Akorn Inc., and Others
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/2307
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN
: +050-5539-1737
No comments:
Post a Comment